Telix to Acquire ITM in $1.65B Radiopharmaceutical Merger — Telix Pharmaceuticals Limited

Event summary

Telix Pharmaceuticals to acquire ITM Isotope Technologies Munich for $1.65 billion, with up to $700 million in additional contingent payments tied to ITM-11 milestones.
ITM shareholders to receive approximately $1.25 billion in Telix shares, with the transaction expected to close by the end of FY 2026.
Combined entity projected to generate over $1.3 billion in unaudited pro forma 2026 revenue, with positive EBITDA expected from 2027.
ITM-11, a Phase 3-ready therapeutic for gastroenteropancreatic neuroendocrine tumors, could accelerate Telix’s entry into the commercial TRT market.
Telix shareholders to own approximately 76.3% of the combined company post-merger.

The big picture

The merger positions Telix as a vertically integrated radiopharmaceutical leader, combining ITM’s isotope production capabilities with Telix’s therapeutic pipeline. This deal reflects broader industry consolidation as demand for targeted radionuclide therapies grows, with the global nuclear medicine market projected to reach $41 billion by 2034. The transaction underscores the strategic value of securing radioisotope supply chains amid increasing competition in the radiopharmaceutical sector.

What we're watching

Regulatory Approvals: Whether ITM-11 secures FDA approval by December 31, 2027, triggering the first $100 million milestone payment.
Integration Execution: The pace at which Telix and ITM align their supply chains, R&D pipelines, and commercial operations post-merger.
Market Expansion: How the combined entity leverages ITM’s global distribution network to scale radiopharmaceutical adoption in emerging markets.